Drugs / semaxanib

Trials 31 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 110 trials
Phase 1 NCT00026377 Nov 2001 → Mar 2002 prostate cancer University of Chicago Completed No outcome recorded
Phase 1 NCT00006257 Nov 2000 → ? cancer of unknown primary site City of Hope Medical Center Completed No outcome recorded
Phase 1 NCT00006247 Aug 2000 → Jul 2003 central nervous system neoplasm Pediatric Brain Tumor Consortium Terminated No outcome recorded
Phase 1 NCT00006155 Aug 2000 → Apr 2001 fallopian tube neoplasm, ovarian cancer, peritoneal neoplasm National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00006000 Aug 2000 → Mar 2004 cancer of unknown primary site Ohio State University Comprehensive Cancer Center Completed No outcome recorded
Phase 1 NCT00005647 May 2000 → Dec 2002 head and neck cancer Case Comprehensive Cancer Center Completed No outcome recorded
Phase 1 NCT00005642 May 2000 → Dec 2002 cancer of unknown primary site Case Comprehensive Cancer Center Completed No outcome recorded
Phase 1 NCT00005822 Apr 2000 → Dec 2002 breast cancer Case Comprehensive Cancer Center Completed No outcome recorded
Phase 1 NCT00003720 Jul 1998 → ? sarcoma Pfizer Completed No outcome recorded
Phase 1 NCT00005996 cancer of unknown primary site Jonsson Comprehensive Cancer Center Unknown No outcome recorded
Phase 1/25 trials
Phase 1/2 NCT00023725 Aug 2001 → Oct 2003 soft tissue sarcoma Radiation Therapy Oncology Group Completed No outcome recorded
Phase 1/2 NCT00023738 Aug 2001 → Oct 2003 sarcoma Radiation Therapy Oncology Group Completed No outcome recorded
Phase 1/2 NCT00004868 Mar 2000 → Sep 2004 central nervous system neoplasm Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Completed No outcome recorded
Phase 1/2 NCT00005818 Mar 2000 → Mar 2003 colon adenocarcinoma, rectum adenocarcinoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/2 NCT00005942 Mar → Dec 2000 acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome with excess blasts, refractory anemia with excess blasts in transformation National Cancer Institute (NCI) Completed No outcome recorded
Phase 213 trials
Phase 2 NCT00017316 Mar 2001 → Sep 2003 cutaneous melanoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00009919 Dec 2000 → Jun 2003 renal cell carcinoma National Cancer Institute (NCI) Terminated No outcome recorded
Phase 2 NCT00006361 Dec 2000 → Jan 2003 cancer of unknown primary site, head and neck cancer, skin cancer Memorial Sloan Kettering Cancer Center Completed No outcome recorded
Phase 2 NCT00006384 Nov 2000 → Feb 2007 kidney cancer City of Hope Medical Center Completed No outcome recorded
Phase 2 NCT00005862 Oct 2000 → Jul 2004 gastrointestinal stromal tumor, sarcoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00006014 Aug 2000 → Feb 2007 malignant mesothelioma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00006001 Aug 2000 → Feb 2007 colorectal cancer National Cancer Institute (NCI) Terminated No outcome recorded
Phase 2 NCT00006003 Jul 2000 → Jul 2003 melanoma National Cancer Institute (NCI) Terminated No outcome recorded
Phase 2 NCT00006013 Jun 2000 → Jan 2003 plasma cell myeloma Fox Chase Cancer Center Completed No outcome recorded
Phase 2 NCT00006002 Jun 2000 → Sep 2002 prostate cancer University of Chicago Completed No outcome recorded
Phase 32 trials
Phase 3 NCT00021281 Dec 2000 → ? colorectal cancer Jonsson Comprehensive Cancer Center Unknown No outcome recorded
Phase 3 NCT00004252 Nov 1999 → Sep 2007 colorectal cancer Pfizer Completed No outcome recorded
Phase not applicable1 trial
NCT00002226 HIV infectious disease, Kaposi's sarcoma SUGEN Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 33 sources stand behind the page.

FieldValueCited text
Known as semaxanib ClinicalTrials.gov intervention name — accepted as the source's own label NCT00017316
26

NCT00003720

NCT00006013

NCT00006247

NCT00006257

NCT00006002

NCT00021281

NCT00005996

NCT00005818

NCT00026260

NCT00005647

NCT00006001

NCT00004868

NCT00006000

NCT00005822

NCT00006384

NCT00009919

NCT00023725

NCT00004252

NCT00006003

NCT00005642

NCT00005862

NCT00005942

NCT00005042

NCT00023738

NCT00006361

NCT00006014

Known as NSC-696819 ChEMBL registry synonym — accepted as the source's own label CHEMBL276711
Known as Semaxinib ChEMBL registry synonym — accepted as the source's own label CHEMBL276711
Known as SU005416 ChEMBL registry synonym — accepted as the source's own label CHEMBL276711
Known as SU5416 SU5416 is a small molecule inhibitor of VEGF-mediated signaling through Flk-1, a transmembrane tyrosine kinase.” PMID 14581348 Oct 2003
6

SU5416 may stop the growth of solid tumors by stopping blood flow to the tumor” NCT00005996

“This is a dose escalation study of SU5416.” NCT00006000

NCT00026377

NCT00006155

NCT00002226

NCT00005931

Action Inhibit “potent and selective inhibitor of the tyrosine kinase activity of FlK-1” NCT00006155
1

“Stem cell growth factor receptor inhibitor” CHEMBL276711

Modality Small molecule “SU5416 is a small molecule inhibitor of VEGF-mediated signaling through Flk-1” PMID 14581348 Oct 2003
Route Intravenous “Study drug is administered as a twice-weekly intravenous injection for 4 weeks.” NCT00002226
Target KIT “Stem cell growth factor receptor inhibitor” CHEMBL276711